Olink and the COVID-19 pandemic

Current number of planned/ongoing studies using Olink = 69

As a provider of protein biomarker solutions for scientists seeking to re-shape future healthcare, Olink is taking the COVID-19 pandemic situation extremely seriously and is committed to support the crucial studies that will help better understand and eventually to better treat the disease.

See all applications related to COVID-19

Actions speak louder than words

Olink’s protein biomarker panels are already being used in a significant number of on-going and planned COVID-19 studies across North America, Europe and Asia, covering a range of objectives, including:

Prediction & prognosis:

  • Understand basic biology and prognosis of disease severity
  • Patient stratification by disease severity
  • Longitudinal sampling (admission to recovery vs. death)
  • Prediction of cytokine release storms in COVID-19 patients
  • Prediction/prevention of ARDS (Acute Respiratory Distress Syndrome)
  • Outcome predictions in CVD patients with COVID19

Therapies:

  • Evaluation of re-purposed therapeutics
  • Patients undergoing plasma-exchange
  • Remdesivir
  • IFNbeta-1
  • IL-6
  • Bradykinin pathways (repurposed rare disease drug)
  • Chloroquine, Hydroxychloroquine,
  • Ruxolitinib
  • Camostat
  • Azithromycin
  • Lopinavir/Ritonavi.
  • Effect of p38 inhibition on COVID-19 patients and cytokine storm
  • Cardiac markers to determine use of ACE2 inhibitors
  • Re-purposed immunotherapy for allergies

Comorbidities:

  • Cancer
  • Cardiovascular disease
  • BMI
  • Renal dysfunction
  • Neurological effects
  • Hematological malignancies
  • Dermatological diseases
  • HIV

You can read much more about how Olink is being used right now in COVID-19 research by downloading our informative and interactive infographic:

covid-pres-img

Olink and drug repositioning and vaccine development for COVID-19

It is critical that solutions for the current COVID-19 pandemic are developed as quickly, efficiently and safely as possible. Pharmaceutical and biotechnology companies are making great efforts to meet the current needs, repurposing drugs and developing both traditional and novel vaccines. Speeding up the process, however, carries many risks and unexpected problems may appear, for example at later stages of vaccine development. Olink’s broad protein biomarker profiling solution can mitigate these risks by providing comprehensive, actionable insights into the relevant biology for these new vaccines or repurposed drugs. This enables problems to be detected at earlier stages, as well as providing a better understanding of how they impact patients in the context of COVID-19. View the brief but comprehensive presentation with more information around these issues to learn more.

IG-CROPPED-IMG_0359-170x170

Olink has the most comprehensive solution available to help to rapidly identify the proteins and pathways involved in COVID-19 pathophysiology and to better understand the disease and its treatment.

I am proud that we are taking our social responsibility during this pandemic by actively supporting the research community to carry out the critical research that is so desperately needed”.

Ida Grundberg PhD, Chief Scientific Officer, Olink

Covid-19-news-web-768x401

Latest news on COVID-19 research using Olink

Olink biomarker assays for COVID-19 research

Our library of high-quality protein assays, which are available as 92-plex panels, is ideally suited for targeted biomarker discovery, with a mix of well-established and exploratory proteins for a broad range of diseases and biological functions. Proteins of particular relevance for COVID-19 research (cytokines, chemokines, and proteins with known links to viral infections and acute respiratory conditions, etc) are listed in the Excel file below (short name, Uniprot ID, and Olink panel(s) in which the assays are available).

2947

Biomarker assays

~881 million

Protein data points generated

907

Publications listed on website

Contact us!